Drugs / SOL-804-F
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06014853 | Aug → Oct 2023 | prostate cancer | Bukwang Pharmaceutical | Completed | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SOL-804-F | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06014853 ↗ |